 Michael Verneris
Concepts (696)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 100 | 2025 | 622 | 15.000 |
Why?
| | Killer Cells, Natural | 52 | 2020 | 449 | 7.480 |
Why?
| | Graft vs Host Disease | 53 | 2025 | 252 | 7.320 |
Why?
| | Transplantation Conditioning | 42 | 2021 | 170 | 5.690 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 37 | 2023 | 289 | 5.360 |
Why?
| | Cord Blood Stem Cell Transplantation | 33 | 2021 | 99 | 5.050 |
Why?
| | Hematologic Neoplasms | 28 | 2024 | 156 | 3.340 |
Why?
| | Leukemia, Myeloid, Acute | 29 | 2025 | 630 | 3.070 |
Why?
| | Transplantation, Homologous | 45 | 2024 | 416 | 2.990 |
Why?
| | Unrelated Donors | 21 | 2021 | 39 | 2.780 |
Why?
| | Leukemia | 20 | 2023 | 240 | 2.690 |
Why?
| | Fetal Blood | 15 | 2017 | 327 | 2.630 |
Why?
| | Hematopoietic Stem Cells | 9 | 2020 | 406 | 2.360 |
Why?
| | Myelodysplastic Syndromes | 16 | 2020 | 135 | 1.960 |
Why?
| | Immunotherapy, Adoptive | 25 | 2025 | 327 | 1.850 |
Why?
| | Immunity, Innate | 7 | 2021 | 828 | 1.810 |
Why?
| | Antibodies, Bispecific | 5 | 2021 | 55 | 1.800 |
Why?
| | Cell Differentiation | 13 | 2022 | 1991 | 1.590 |
Why?
| | Neoplasm, Residual | 7 | 2021 | 133 | 1.560 |
Why?
| | Haplotypes | 4 | 2021 | 494 | 1.410 |
Why?
| | Receptors, Antigen, T-Cell | 14 | 2025 | 718 | 1.400 |
Why?
| | Bone Marrow Transplantation | 12 | 2017 | 286 | 1.400 |
Why?
| | Recurrence | 32 | 2023 | 1060 | 1.390 |
Why?
| | Disease-Free Survival | 29 | 2021 | 686 | 1.360 |
Why?
| | CD56 Antigen | 9 | 2020 | 35 | 1.360 |
Why?
| | Cytomegalovirus Infections | 8 | 2024 | 192 | 1.330 |
Why?
| | Child | 94 | 2025 | 21935 | 1.310 |
Why?
| | Humans | 223 | 2025 | 137585 | 1.260 |
Why?
| | Cell- and Tissue-Based Therapy | 4 | 2024 | 81 | 1.210 |
Why?
| | Child, Preschool | 64 | 2025 | 11074 | 1.180 |
Why?
| | HLA Antigens | 9 | 2017 | 240 | 1.180 |
Why?
| | Interleukins | 4 | 2015 | 250 | 1.160 |
Why?
| | Adolescent | 89 | 2025 | 21513 | 1.150 |
Why?
| | Antineoplastic Agents | 13 | 2021 | 2129 | 1.130 |
Why?
| | Young Adult | 68 | 2025 | 13209 | 1.130 |
Why?
| | Immunotherapy | 10 | 2024 | 641 | 1.110 |
Why?
| | Receptors, IgG | 8 | 2019 | 75 | 1.110 |
Why?
| | Lymphoid Tissue | 3 | 2021 | 75 | 1.070 |
Why?
| | T-Lymphocytes, Helper-Inducer | 2 | 2019 | 137 | 1.050 |
Why?
| | Cytomegalovirus | 9 | 2024 | 157 | 1.020 |
Why?
| | Virus Activation | 5 | 2024 | 88 | 1.000 |
Why?
| | Bone Neoplasms | 5 | 2025 | 247 | 1.000 |
Why?
| | Graft Survival | 9 | 2018 | 535 | 1.000 |
Why?
| | Infant | 49 | 2025 | 9465 | 0.970 |
Why?
| | Receptors, KIR | 9 | 2015 | 98 | 0.950 |
Why?
| | Lymphocytes | 6 | 2020 | 397 | 0.950 |
Why?
| | B7 Antigens | 2 | 2024 | 13 | 0.950 |
Why?
| | Adult | 95 | 2024 | 37929 | 0.940 |
Why?
| | Cytokines | 10 | 2018 | 2085 | 0.930 |
Why?
| | Interleukin-8 | 2 | 2024 | 268 | 0.930 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 80 | 0.920 |
Why?
| | Cryopreservation | 2 | 2017 | 100 | 0.910 |
Why?
| | Survival Analysis | 23 | 2020 | 1325 | 0.910 |
Why?
| | Histocompatibility Testing | 10 | 2018 | 126 | 0.910 |
Why?
| | Antigens, CD | 6 | 2019 | 521 | 0.910 |
Why?
| | Whole-Body Irradiation | 8 | 2018 | 78 | 0.900 |
Why?
| | Male | 115 | 2025 | 67762 | 0.890 |
Why?
| | Female | 119 | 2025 | 73304 | 0.860 |
Why?
| | T-Lymphocytes | 14 | 2025 | 1996 | 0.850 |
Why?
| | Tissue Donors | 10 | 2024 | 425 | 0.850 |
Why?
| | Pluripotent Stem Cells | 2 | 2022 | 80 | 0.840 |
Why?
| | Histocompatibility | 6 | 2019 | 28 | 0.840 |
Why?
| | Treatment Outcome | 44 | 2021 | 10811 | 0.840 |
Why?
| | Adoptive Transfer | 4 | 2017 | 219 | 0.830 |
Why?
| | Sarcoma, Ewing | 4 | 2025 | 97 | 0.810 |
Why?
| | Middle Aged | 73 | 2024 | 33479 | 0.790 |
Why?
| | Graft vs Leukemia Effect | 3 | 2013 | 12 | 0.790 |
Why?
| | Stem Cell Transplantation | 3 | 2019 | 176 | 0.780 |
Why?
| | Hemangioblasts | 1 | 2022 | 4 | 0.780 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 3 | 2018 | 24 | 0.780 |
Why?
| | Lymphocyte Depletion | 5 | 2019 | 135 | 0.770 |
Why?
| | HLA-C Antigens | 3 | 2016 | 35 | 0.760 |
Why?
| | Lymphoid Progenitor Cells | 2 | 2020 | 11 | 0.730 |
Why?
| | Receptors, Immunologic | 6 | 2016 | 216 | 0.730 |
Why?
| | Interferon-gamma | 9 | 2014 | 789 | 0.700 |
Why?
| | CD48 Antigen | 1 | 2020 | 2 | 0.700 |
Why?
| | Signaling Lymphocytic Activation Molecule Family | 1 | 2020 | 7 | 0.700 |
Why?
| | Bone Marrow | 9 | 2017 | 286 | 0.690 |
Why?
| | Receptors, Prolactin | 1 | 2020 | 7 | 0.670 |
Why?
| | Leukemia, Myeloid | 2 | 2017 | 45 | 0.660 |
Why?
| | Smad7 Protein | 1 | 2020 | 19 | 0.660 |
Why?
| | Lymphopoiesis | 1 | 2020 | 26 | 0.660 |
Why?
| | Transplantation, Autologous | 5 | 2019 | 238 | 0.650 |
Why?
| | Burkitt Lymphoma | 4 | 2023 | 60 | 0.650 |
Why?
| | Prolactin | 1 | 2020 | 96 | 0.650 |
Why?
| | Antigens, CD19 | 10 | 2023 | 123 | 0.650 |
Why?
| | Monocytes | 3 | 2020 | 563 | 0.650 |
Why?
| | Transplantation Chimera | 2 | 2019 | 54 | 0.630 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2020 | 165 | 0.610 |
Why?
| | GATA3 Transcription Factor | 1 | 2019 | 26 | 0.610 |
Why?
| | Cells, Cultured | 15 | 2022 | 4193 | 0.610 |
Why?
| | Interleukin-2 | 5 | 2019 | 455 | 0.610 |
Why?
| | Cell Proliferation | 12 | 2019 | 2475 | 0.610 |
Why?
| | Crohn Disease | 1 | 2022 | 243 | 0.610 |
Why?
| | Interleukin-15 | 5 | 2019 | 98 | 0.600 |
Why?
| | Allografts | 13 | 2021 | 146 | 0.580 |
Why?
| | Immune Reconstitution | 1 | 2018 | 8 | 0.580 |
Why?
| | Adipokines | 1 | 2018 | 49 | 0.580 |
Why?
| | Piperazines | 3 | 2009 | 350 | 0.570 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2022 | 351 | 0.570 |
Why?
| | Cell Lineage | 3 | 2020 | 350 | 0.570 |
Why?
| | Delayed Graft Function | 1 | 2018 | 33 | 0.570 |
Why?
| | Survival Rate | 18 | 2020 | 1972 | 0.560 |
Why?
| | Histocompatibility Antigens Class I | 4 | 2019 | 203 | 0.560 |
Why?
| | Aged | 48 | 2024 | 23961 | 0.560 |
Why?
| | Retrospective Studies | 36 | 2023 | 15657 | 0.550 |
Why?
| | Gene Expression Regulation | 4 | 2019 | 2607 | 0.540 |
Why?
| | Antigens, CD34 | 4 | 2022 | 88 | 0.530 |
Why?
| | Prognosis | 17 | 2025 | 4030 | 0.530 |
Why?
| | T-Lymphocytes, Regulatory | 4 | 2015 | 385 | 0.530 |
Why?
| | Pyrimidines | 3 | 2009 | 470 | 0.530 |
Why?
| | Acute Disease | 17 | 2019 | 1007 | 0.530 |
Why?
| | Stromal Cells | 4 | 2011 | 112 | 0.520 |
Why?
| | Blood Donors | 4 | 2016 | 105 | 0.520 |
Why?
| | Siblings | 7 | 2019 | 228 | 0.520 |
Why?
| | CD8-Positive T-Lymphocytes | 7 | 2025 | 900 | 0.520 |
Why?
| | Myeloid Progenitor Cells | 2 | 2020 | 17 | 0.510 |
Why?
| | Cell Degranulation | 3 | 2013 | 41 | 0.500 |
Why?
| | Mice | 26 | 2025 | 17787 | 0.500 |
Why?
| | Bone Marrow Cells | 3 | 2020 | 316 | 0.500 |
Why?
| | Time Factors | 17 | 2019 | 6828 | 0.490 |
Why?
| | Lymphoma, B-Cell | 4 | 2023 | 106 | 0.490 |
Why?
| | Lymphocyte Activation | 12 | 2016 | 1142 | 0.480 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 25 | 1 | 2015 | 5 | 0.480 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2015 | 8 | 0.480 |
Why?
| | Self Tolerance | 2 | 2013 | 28 | 0.480 |
Why?
| | Pulmonary Embolism | 2 | 2010 | 226 | 0.470 |
Why?
| | Neoplasms | 10 | 2022 | 2671 | 0.470 |
Why?
| | Up-Regulation | 3 | 2015 | 843 | 0.470 |
Why?
| | Single-Cell Analysis | 3 | 2025 | 313 | 0.460 |
Why?
| | Immunologic Memory | 5 | 2025 | 353 | 0.450 |
Why?
| | Receptors, Calcitriol | 1 | 2014 | 55 | 0.440 |
Why?
| | Calcitriol | 1 | 2014 | 58 | 0.440 |
Why?
| | Mitochondria | 4 | 2021 | 948 | 0.430 |
Why?
| | Recombinant Fusion Proteins | 5 | 2021 | 665 | 0.430 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2009 | 122 | 0.420 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2016 | 1091 | 0.410 |
Why?
| | Chromosomes, Human, Pair 7 | 1 | 2013 | 18 | 0.410 |
Why?
| | Donor Selection | 4 | 2018 | 77 | 0.410 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2013 | 30 | 0.410 |
Why?
| | Single-Chain Antibodies | 1 | 2013 | 18 | 0.410 |
Why?
| | Mycophenolic Acid | 3 | 2016 | 117 | 0.400 |
Why?
| | Cell Line, Tumor | 11 | 2024 | 3412 | 0.400 |
Why?
| | Vitamins | 1 | 2014 | 185 | 0.400 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily C | 4 | 2015 | 8 | 0.400 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2021 | 1692 | 0.390 |
Why?
| | Immunophenotyping | 8 | 2019 | 318 | 0.390 |
Why?
| | Cytotoxicity, Immunologic | 10 | 2016 | 224 | 0.390 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2018 | 1079 | 0.390 |
Why?
| | Animals | 31 | 2025 | 36940 | 0.390 |
Why?
| | Chromosome Aberrations | 1 | 2013 | 156 | 0.380 |
Why?
| | Metabolic Syndrome | 1 | 2016 | 354 | 0.380 |
Why?
| | Osteosarcoma | 2 | 2024 | 74 | 0.380 |
Why?
| | Fibroblast Growth Factor 7 | 1 | 2011 | 15 | 0.370 |
Why?
| | Lymphocyte Count | 4 | 2017 | 148 | 0.370 |
Why?
| | Remission Induction | 9 | 2018 | 288 | 0.370 |
Why?
| | Carcinoma | 1 | 2013 | 240 | 0.350 |
Why?
| | Cell Communication | 1 | 2013 | 315 | 0.350 |
Why?
| | Immunosuppressive Agents | 4 | 2015 | 890 | 0.350 |
Why?
| | Neutropenia | 2 | 2025 | 146 | 0.340 |
Why?
| | Lymphocyte Subsets | 3 | 2021 | 87 | 0.340 |
Why?
| | Graft vs Tumor Effect | 3 | 2017 | 8 | 0.340 |
Why?
| | Sialic Acid Binding Ig-like Lectin 3 | 3 | 2016 | 9 | 0.340 |
Why?
| | Salvage Therapy | 1 | 2011 | 142 | 0.340 |
Why?
| | K562 Cells | 6 | 2014 | 89 | 0.330 |
Why?
| | Heparin | 1 | 2011 | 261 | 0.330 |
Why?
| | Risk Factors | 21 | 2025 | 10388 | 0.320 |
Why?
| | Incidence | 8 | 2019 | 2804 | 0.320 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2021 | 190 | 0.310 |
Why?
| | Myeloablative Agonists | 5 | 2016 | 22 | 0.310 |
Why?
| | Body Mass Index | 1 | 2018 | 2389 | 0.310 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2024 | 872 | 0.310 |
Why?
| | Natural Cytotoxicity Triggering Receptor 3 | 1 | 2008 | 2 | 0.300 |
Why?
| | Medical Oncology | 1 | 2011 | 289 | 0.300 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2008 | 41 | 0.300 |
Why?
| | Infant, Newborn | 9 | 2019 | 6079 | 0.300 |
Why?
| | Philadelphia Chromosome | 1 | 2008 | 18 | 0.300 |
Why?
| | Cyclosporine | 3 | 2016 | 268 | 0.300 |
Why?
| | Influenza Vaccines | 2 | 2016 | 539 | 0.300 |
Why?
| | Hematopoiesis | 3 | 2020 | 192 | 0.290 |
Why?
| | Lymphocyte Transfusion | 3 | 2016 | 21 | 0.290 |
Why?
| | Antibodies | 5 | 2018 | 410 | 0.290 |
Why?
| | Gene Expression Regulation, Leukemic | 2 | 2019 | 56 | 0.290 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 73 | 0.290 |
Why?
| | Natural Killer T-Cells | 1 | 2008 | 67 | 0.280 |
Why?
| | Epidermal Growth Factor | 3 | 2017 | 177 | 0.280 |
Why?
| | Kaplan-Meier Estimate | 6 | 2021 | 889 | 0.280 |
Why?
| | Cell Count | 3 | 2014 | 324 | 0.280 |
Why?
| | Follow-Up Studies | 9 | 2020 | 5131 | 0.270 |
Why?
| | Chronic Disease | 6 | 2023 | 1793 | 0.270 |
Why?
| | Coculture Techniques | 5 | 2020 | 239 | 0.270 |
Why?
| | GPI-Linked Proteins | 4 | 2019 | 73 | 0.270 |
Why?
| | Polymorphism, Genetic | 3 | 2016 | 660 | 0.270 |
Why?
| | Alleles | 4 | 2017 | 891 | 0.260 |
Why?
| | HLA-DP beta-Chains | 2 | 2017 | 86 | 0.260 |
Why?
| | Matrix Metalloproteinases | 1 | 2007 | 95 | 0.250 |
Why?
| | Peritoneal Dialysis | 1 | 2007 | 97 | 0.250 |
Why?
| | Hyperglycemia | 2 | 2020 | 347 | 0.250 |
Why?
| | Cell Separation | 3 | 2020 | 318 | 0.240 |
Why?
| | Neuroblastoma | 1 | 2007 | 160 | 0.240 |
Why?
| | Apoptosis | 7 | 2011 | 2553 | 0.240 |
Why?
| | CD57 Antigens | 3 | 2015 | 17 | 0.240 |
Why?
| | Lactobacillus plantarum | 1 | 2025 | 1 | 0.240 |
Why?
| | Heart Diseases | 1 | 2009 | 346 | 0.240 |
Why?
| | Neoplasms, Experimental | 2 | 2005 | 176 | 0.240 |
Why?
| | Genetic Heterogeneity | 1 | 2025 | 59 | 0.230 |
Why?
| | Imatinib Mesylate | 3 | 2009 | 79 | 0.230 |
Why?
| | Clonal Evolution | 1 | 2025 | 45 | 0.230 |
Why?
| | Radiotherapy, Intensity-Modulated | 3 | 2013 | 142 | 0.230 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 2 | 2023 | 30 | 0.230 |
Why?
| | Chimerism | 2 | 2021 | 31 | 0.230 |
Why?
| | Probiotics | 1 | 2025 | 54 | 0.230 |
Why?
| | Cytomegalovirus Vaccines | 1 | 2024 | 3 | 0.220 |
Why?
| | Blood Platelets | 3 | 2021 | 408 | 0.220 |
Why?
| | Diphtheria Toxin | 2 | 2015 | 66 | 0.220 |
Why?
| | Neoplasm Proteins | 3 | 2017 | 434 | 0.220 |
Why?
| | Risk | 3 | 2018 | 912 | 0.220 |
Why?
| | Benzamides | 3 | 2009 | 216 | 0.210 |
Why?
| | Membrane Proteins | 8 | 2015 | 1164 | 0.210 |
Why?
| | Follistatin | 3 | 2019 | 12 | 0.210 |
Why?
| | Lymphoma | 3 | 2003 | 208 | 0.210 |
Why?
| | Major Histocompatibility Complex | 2 | 2018 | 227 | 0.210 |
Why?
| | Clinical Trials as Topic | 2 | 2025 | 1050 | 0.210 |
Why?
| | Cohort Studies | 12 | 2021 | 5742 | 0.210 |
Why?
| | Endoglin | 3 | 2019 | 19 | 0.210 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 31 | 0.200 |
Why?
| | Receptors, Natural Killer Cell | 4 | 2014 | 16 | 0.200 |
Why?
| | Neutrophils | 4 | 2017 | 1238 | 0.200 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2018 | 801 | 0.200 |
Why?
| | Biomarkers, Tumor | 4 | 2025 | 1276 | 0.200 |
Why?
| | Gastrointestinal Diseases | 1 | 2025 | 209 | 0.200 |
Why?
| | Receptor, ErbB-2 | 1 | 2005 | 341 | 0.200 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2024 | 98 | 0.200 |
Why?
| | Protein Kinase Inhibitors | 1 | 2009 | 916 | 0.200 |
Why?
| | Flow Cytometry | 5 | 2020 | 1178 | 0.190 |
Why?
| | Mutation | 4 | 2019 | 3958 | 0.190 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1313 | 0.190 |
Why?
| | Hodgkin Disease | 2 | 2001 | 138 | 0.190 |
Why?
| | fms-Like Tyrosine Kinase 3 | 2 | 2020 | 48 | 0.190 |
Why?
| | Combined Modality Therapy | 6 | 2021 | 1236 | 0.190 |
Why?
| | Maximum Tolerated Dose | 3 | 2017 | 199 | 0.190 |
Why?
| | Sarcoma | 1 | 2024 | 188 | 0.190 |
Why?
| | Leukemia, Myelomonocytic, Juvenile | 1 | 2021 | 4 | 0.180 |
Why?
| | Virus Diseases | 1 | 2024 | 212 | 0.180 |
Why?
| | Proteins | 4 | 2018 | 1009 | 0.180 |
Why?
| | Multivariate Analysis | 5 | 2014 | 1509 | 0.180 |
Why?
| | Thrombopoietin | 1 | 2021 | 5 | 0.180 |
Why?
| | Severity of Illness Index | 4 | 2021 | 2828 | 0.180 |
Why?
| | Signal Transduction | 7 | 2020 | 5079 | 0.180 |
Why?
| | Genetic Variation | 2 | 2017 | 991 | 0.180 |
Why?
| | fas Receptor | 2 | 2003 | 95 | 0.180 |
Why?
| | B-Lymphocytes | 2 | 2025 | 847 | 0.180 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2018 | 2189 | 0.180 |
Why?
| | CD52 Antigen | 1 | 2020 | 4 | 0.180 |
Why?
| | CD3 Complex | 2 | 2001 | 106 | 0.180 |
Why?
| | Carcinoma, Papillary | 1 | 2001 | 81 | 0.170 |
Why?
| | Heterografts | 1 | 2021 | 138 | 0.170 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2020 | 14 | 0.170 |
Why?
| | Receptors, Fc | 1 | 2021 | 53 | 0.170 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2022 | 210 | 0.170 |
Why?
| | Cell Survival | 2 | 2014 | 1120 | 0.170 |
Why?
| | Cell Culture Techniques | 4 | 2011 | 363 | 0.170 |
Why?
| | Gene Knockout Techniques | 1 | 2020 | 118 | 0.170 |
Why?
| | Primary Cell Culture | 1 | 2020 | 171 | 0.160 |
Why?
| | Neoplasms, Second Primary | 1 | 2001 | 118 | 0.160 |
Why?
| | Graft Rejection | 4 | 2021 | 624 | 0.160 |
Why?
| | Immune System | 1 | 2021 | 177 | 0.160 |
Why?
| | Arabidopsis Proteins | 1 | 2000 | 75 | 0.160 |
Why?
| | Pneumococcal Vaccines | 1 | 2021 | 142 | 0.160 |
Why?
| | Cell Self Renewal | 1 | 2019 | 56 | 0.160 |
Why?
| | Species Specificity | 1 | 2020 | 585 | 0.160 |
Why?
| | Blast Crisis | 2 | 2017 | 33 | 0.160 |
Why?
| | Mice, SCID | 5 | 2021 | 367 | 0.150 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2019 | 27 | 0.150 |
Why?
| | Linkage Disequilibrium | 2 | 2016 | 268 | 0.150 |
Why?
| | Radiotherapy Dosage | 3 | 2016 | 268 | 0.150 |
Why?
| | Busulfan | 1 | 2018 | 16 | 0.150 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2019 | 85 | 0.150 |
Why?
| | Leukocytes, Mononuclear | 1 | 2021 | 558 | 0.150 |
Why?
| | Pilot Projects | 2 | 2021 | 1710 | 0.140 |
Why?
| | Biomarkers | 6 | 2015 | 4149 | 0.140 |
Why?
| | HLA-DRB1 Chains | 1 | 2018 | 112 | 0.140 |
Why?
| | Prospective Studies | 6 | 2023 | 7604 | 0.140 |
Why?
| | Telomere Homeostasis | 1 | 2017 | 34 | 0.140 |
Why?
| | Pediatrics | 2 | 2019 | 1101 | 0.140 |
Why?
| | Cell Line | 3 | 2011 | 2847 | 0.140 |
Why?
| | Epithelial Cell Adhesion Molecule | 2 | 2016 | 13 | 0.130 |
Why?
| | Antibodies, Neoplasm | 1 | 2017 | 34 | 0.130 |
Why?
| | Vidarabine | 4 | 2022 | 33 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 3 | 2017 | 2691 | 0.130 |
Why?
| | Homeostasis | 1 | 2021 | 621 | 0.130 |
Why?
| | Dideoxynucleosides | 1 | 2017 | 21 | 0.130 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily B | 1 | 2016 | 10 | 0.130 |
Why?
| | Thyroid Neoplasms | 1 | 2001 | 343 | 0.130 |
Why?
| | Vascularized Composite Allotransplantation | 1 | 2017 | 31 | 0.130 |
Why?
| | Proportional Hazards Models | 3 | 2015 | 1266 | 0.130 |
Why?
| | Receptors, OX40 | 1 | 2016 | 15 | 0.130 |
Why?
| | Roseolovirus Infections | 1 | 2016 | 8 | 0.130 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2017 | 55 | 0.130 |
Why?
| | Central Nervous System Neoplasms | 1 | 2019 | 156 | 0.130 |
Why?
| | Ambulatory Care | 1 | 2021 | 546 | 0.130 |
Why?
| | Herpesvirus 6, Human | 1 | 2016 | 14 | 0.130 |
Why?
| | Secondary Prevention | 3 | 2014 | 233 | 0.130 |
Why?
| | Gene Expression Profiling | 5 | 2025 | 1774 | 0.130 |
Why?
| | Lymphoma, Non-Hodgkin | 2 | 2015 | 87 | 0.130 |
Why?
| | 5-Methylcytosine | 1 | 2016 | 22 | 0.130 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2016 | 19 | 0.130 |
Why?
| | Transplantation | 1 | 2016 | 34 | 0.130 |
Why?
| | Whole Body Imaging | 1 | 2016 | 25 | 0.130 |
Why?
| | Age Factors | 5 | 2021 | 3295 | 0.130 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2016 | 35 | 0.130 |
Why?
| | Leuprolide | 1 | 2016 | 20 | 0.130 |
Why?
| | Sociobiology | 1 | 2015 | 2 | 0.120 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2017 | 181 | 0.120 |
Why?
| | Antibodies, Monoclonal | 3 | 2017 | 1430 | 0.120 |
Why?
| | Immune System Diseases | 1 | 2016 | 39 | 0.120 |
Why?
| | Interleukin-23 Subunit p19 | 1 | 2015 | 6 | 0.120 |
Why?
| | T-Lymphocyte Subsets | 1 | 2018 | 417 | 0.120 |
Why?
| | Mortality | 1 | 2018 | 362 | 0.120 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2016 | 66 | 0.120 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 399 | 0.120 |
Why?
| | Receptors, KIR2DL1 | 1 | 2015 | 19 | 0.120 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 26 | 0.120 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 1 | 2015 | 13 | 0.120 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 2 | 2013 | 130 | 0.120 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2016 | 175 | 0.120 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 81 | 0.120 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 294 | 0.120 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2020 | 860 | 0.120 |
Why?
| | Radiotherapy, Computer-Assisted | 1 | 2014 | 12 | 0.120 |
Why?
| | Cyclophosphamide | 4 | 2014 | 247 | 0.110 |
Why?
| | Prostatic Neoplasms | 2 | 2013 | 1043 | 0.110 |
Why?
| | Sirolimus | 1 | 2016 | 276 | 0.110 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2016 | 212 | 0.110 |
Why?
| | Radiotherapy, Conformal | 1 | 2014 | 70 | 0.110 |
Why?
| | Ovary | 1 | 2016 | 221 | 0.110 |
Why?
| | DNA, Viral | 1 | 2016 | 364 | 0.110 |
Why?
| | Models, Biological | 2 | 2020 | 1783 | 0.110 |
Why?
| | Disease Models, Animal | 3 | 2021 | 4295 | 0.110 |
Why?
| | Radiation Dosage | 1 | 2015 | 179 | 0.110 |
Why?
| | DNA Repair | 1 | 2016 | 231 | 0.110 |
Why?
| | DNA Methylation | 2 | 2016 | 643 | 0.110 |
Why?
| | Mice, Inbred NOD | 4 | 2021 | 601 | 0.110 |
Why?
| | Arabinonucleosides | 1 | 2013 | 8 | 0.110 |
Why?
| | Hypoglycemia | 1 | 2019 | 445 | 0.110 |
Why?
| | Adenine Nucleotides | 1 | 2013 | 23 | 0.110 |
Why?
| | Toll-Like Receptor 5 | 1 | 2013 | 14 | 0.110 |
Why?
| | Dendritic Cells | 1 | 2017 | 483 | 0.110 |
Why?
| | Receptors, Notch | 1 | 2014 | 88 | 0.110 |
Why?
| | Risk Assessment | 5 | 2025 | 3457 | 0.110 |
Why?
| | Luminescent Measurements | 3 | 2002 | 76 | 0.110 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 1995 | 184 | 0.110 |
Why?
| | Tomography, Spiral Computed | 2 | 2014 | 32 | 0.100 |
Why?
| | Phantoms, Imaging | 1 | 2014 | 152 | 0.100 |
Why?
| | CTLA-4 Antigen | 1 | 2014 | 99 | 0.100 |
Why?
| | RNA, Messenger | 4 | 2013 | 2833 | 0.100 |
Why?
| | Embryonic Stem Cells | 2 | 2017 | 129 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 3 | 2016 | 2426 | 0.100 |
Why?
| | Binding Sites | 1 | 2016 | 1303 | 0.100 |
Why?
| | Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2013 | 14 | 0.100 |
Why?
| | Interleukin-1beta | 1 | 2015 | 372 | 0.100 |
Why?
| | ADAM Proteins | 1 | 2013 | 61 | 0.100 |
Why?
| | Pericardial Effusion | 1 | 2013 | 19 | 0.100 |
Why?
| | Clinical Protocols | 1 | 2014 | 271 | 0.100 |
Why?
| | Antiviral Agents | 1 | 2019 | 744 | 0.100 |
Why?
| | Receptors, Cytokine | 1 | 2013 | 36 | 0.100 |
Why?
| | Living Donors | 1 | 2015 | 295 | 0.100 |
Why?
| | Recovery of Function | 1 | 2017 | 653 | 0.100 |
Why?
| | Body Size | 1 | 2013 | 108 | 0.100 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2012 | 36 | 0.100 |
Why?
| | Machine Learning | 1 | 2018 | 493 | 0.100 |
Why?
| | Health Status Indicators | 1 | 2013 | 171 | 0.100 |
Why?
| | Survivors | 1 | 2016 | 493 | 0.100 |
Why?
| | Cell Adhesion Molecules | 1 | 2013 | 181 | 0.090 |
Why?
| | Apolipoprotein C-III | 2 | 2009 | 12 | 0.090 |
Why?
| | Galectins | 1 | 2012 | 24 | 0.090 |
Why?
| | Promoter Regions, Genetic | 1 | 2016 | 1250 | 0.090 |
Why?
| | CD4 Lymphocyte Count | 1 | 2012 | 269 | 0.090 |
Why?
| | Antigens, Viral | 1 | 2012 | 178 | 0.090 |
Why?
| | Antibody Formation | 1 | 2013 | 298 | 0.090 |
Why?
| | Taxoids | 1 | 2011 | 102 | 0.090 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily D | 1 | 2011 | 1 | 0.090 |
Why?
| | Proteoglycans | 1 | 2011 | 107 | 0.090 |
Why?
| | Ligands | 3 | 2021 | 664 | 0.090 |
Why?
| | Antigens, CD20 | 1 | 2011 | 29 | 0.090 |
Why?
| | Leukemia, Experimental | 2 | 2009 | 27 | 0.090 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2013 | 215 | 0.090 |
Why?
| | Colony-Forming Units Assay | 1 | 2010 | 91 | 0.090 |
Why?
| | Fas Ligand Protein | 2 | 2001 | 60 | 0.090 |
Why?
| | Observer Variation | 1 | 2011 | 343 | 0.090 |
Why?
| | Colonic Neoplasms | 1 | 2013 | 258 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2011 | 67 | 0.090 |
Why?
| | Bone and Bones | 1 | 2013 | 317 | 0.080 |
Why?
| | HL-60 Cells | 3 | 2016 | 34 | 0.080 |
Why?
| | Antigens, Neoplasm | 1 | 2013 | 319 | 0.080 |
Why?
| | Influenza, Human | 1 | 2016 | 622 | 0.080 |
Why?
| | Blood Glucose | 1 | 2020 | 2186 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2017 | 654 | 0.080 |
Why?
| | Umbilical Cord | 1 | 2010 | 85 | 0.080 |
Why?
| | Genotype | 1 | 2015 | 1916 | 0.080 |
Why?
| | Tumor Microenvironment | 2 | 2025 | 674 | 0.080 |
Why?
| | MicroRNAs | 1 | 2016 | 692 | 0.080 |
Why?
| | Diagnostic Imaging | 2 | 2002 | 332 | 0.080 |
Why?
| | Serologic Tests | 1 | 2009 | 54 | 0.080 |
Why?
| | Predictive Value of Tests | 3 | 2018 | 2031 | 0.080 |
Why?
| | Registries | 2 | 2015 | 2035 | 0.080 |
Why?
| | Graft vs Host Reaction | 1 | 2008 | 1 | 0.080 |
Why?
| | Glycosides | 1 | 2009 | 36 | 0.070 |
Why?
| | Leukemic Infiltration | 1 | 2008 | 5 | 0.070 |
Why?
| | Thoracic Vertebrae | 1 | 2009 | 77 | 0.070 |
Why?
| | Databases, Factual | 1 | 2014 | 1357 | 0.070 |
Why?
| | Hydrocortisone | 1 | 2010 | 322 | 0.070 |
Why?
| | Longitudinal Studies | 2 | 2015 | 2844 | 0.070 |
Why?
| | Membrane Glycoproteins | 2 | 2001 | 500 | 0.070 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily K | 2 | 2005 | 7 | 0.070 |
Why?
| | Head and Neck Neoplasms | 1 | 2013 | 606 | 0.070 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2167 | 0.070 |
Why?
| | Monomeric GTP-Binding Proteins | 1 | 2007 | 14 | 0.070 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2007 | 124 | 0.070 |
Why?
| | NFATC Transcription Factors | 1 | 2007 | 95 | 0.070 |
Why?
| | Double-Blind Method | 1 | 2011 | 1993 | 0.060 |
Why?
| | Case-Control Studies | 4 | 2020 | 3556 | 0.060 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2006 | 24 | 0.060 |
Why?
| | Antigens, Differentiation | 1 | 2006 | 83 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2018 | 804 | 0.060 |
Why?
| | Fibroma, Desmoplastic | 1 | 2006 | 2 | 0.060 |
Why?
| | Central Nervous System | 1 | 2008 | 258 | 0.060 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2006 | 14 | 0.060 |
Why?
| | Drug Monitoring | 1 | 2007 | 218 | 0.060 |
Why?
| | Regression Analysis | 1 | 2008 | 1024 | 0.060 |
Why?
| | Liver Diseases | 1 | 2009 | 315 | 0.060 |
Why?
| | Immunohistochemistry | 2 | 2011 | 1738 | 0.060 |
Why?
| | Killer Cells, Lymphokine-Activated | 2 | 2002 | 12 | 0.060 |
Why?
| | Meningitis, Viral | 1 | 2005 | 21 | 0.060 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2025 | 1396 | 0.060 |
Why?
| | Bariatric Surgery | 1 | 2009 | 217 | 0.060 |
Why?
| | United States | 4 | 2024 | 14841 | 0.060 |
Why?
| | Reactive Oxygen Species | 2 | 2020 | 622 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2007 | 268 | 0.060 |
Why?
| | Calcium Signaling | 1 | 2007 | 249 | 0.060 |
Why?
| | Forkhead Box Protein O1 | 1 | 2025 | 33 | 0.060 |
Why?
| | Trastuzumab | 1 | 2005 | 96 | 0.060 |
Why?
| | Metformin | 1 | 2009 | 331 | 0.060 |
Why?
| | Anemia | 1 | 2006 | 170 | 0.060 |
Why?
| | RNA, Small Interfering | 2 | 2005 | 622 | 0.060 |
Why?
| | Inflammation | 1 | 2016 | 2837 | 0.060 |
Why?
| | Aged, 80 and over | 4 | 2020 | 7635 | 0.060 |
Why?
| | Jurkat Cells | 2 | 2017 | 134 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2019 | 545 | 0.060 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2025 | 80 | 0.060 |
Why?
| | Receptors, Chemokine | 1 | 2024 | 47 | 0.050 |
Why?
| | Pharmacovigilance | 1 | 2024 | 23 | 0.050 |
Why?
| | Hemoglobins | 1 | 2006 | 353 | 0.050 |
Why?
| | Mice, Inbred BALB C | 3 | 2002 | 1272 | 0.050 |
Why?
| | RNA Interference | 1 | 2005 | 469 | 0.050 |
Why?
| | Plasma | 1 | 2005 | 212 | 0.050 |
Why?
| | Cell Nucleus | 1 | 2007 | 620 | 0.050 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2024 | 63 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2021 | 3015 | 0.050 |
Why?
| | Immunocompromised Host | 1 | 2005 | 202 | 0.050 |
Why?
| | Phenotype | 3 | 2021 | 3196 | 0.050 |
Why?
| | Erythroid Precursor Cells | 1 | 2003 | 5 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2024 | 166 | 0.050 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2023 | 45 | 0.050 |
Why?
| | Feasibility Studies | 2 | 2019 | 956 | 0.050 |
Why?
| | Dogs | 1 | 2024 | 413 | 0.050 |
Why?
| | Mice, Inbred C57BL | 4 | 2025 | 5757 | 0.050 |
Why?
| | Pregnancy | 3 | 2010 | 6763 | 0.050 |
Why?
| | Physicians | 1 | 2011 | 910 | 0.050 |
Why?
| | beta-Thalassemia | 1 | 2003 | 36 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 683 | 0.050 |
Why?
| | Enterovirus Infections | 1 | 2005 | 177 | 0.050 |
Why?
| | Sepsis | 1 | 2009 | 617 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 452 | 0.050 |
Why?
| | Oxidants | 1 | 2003 | 111 | 0.050 |
Why?
| | Postoperative Complications | 2 | 2015 | 2654 | 0.050 |
Why?
| | Liver | 1 | 2011 | 1943 | 0.050 |
Why?
| | Social Class | 1 | 2024 | 282 | 0.050 |
Why?
| | In Vitro Techniques | 1 | 2003 | 1092 | 0.050 |
Why?
| | Norpregnenes | 1 | 2001 | 4 | 0.050 |
Why?
| | Werner Syndrome | 1 | 2001 | 2 | 0.050 |
Why?
| | Creatine Kinase | 1 | 2001 | 79 | 0.050 |
Why?
| | Dactinomycin | 1 | 2001 | 28 | 0.050 |
Why?
| | Femoral Neoplasms | 1 | 2001 | 9 | 0.050 |
Why?
| | Perforin | 1 | 2001 | 19 | 0.040 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2001 | 16 | 0.040 |
Why?
| | Thoracotomy | 1 | 2001 | 75 | 0.040 |
Why?
| | Probability | 2 | 2013 | 304 | 0.040 |
Why?
| | Vincristine | 1 | 2001 | 116 | 0.040 |
Why?
| | Hypersensitivity, Immediate | 1 | 2001 | 44 | 0.040 |
Why?
| | Cycloheximide | 1 | 2000 | 55 | 0.040 |
Why?
| | Thyroidectomy | 1 | 2001 | 106 | 0.040 |
Why?
| | HIV Infections | 1 | 1995 | 2836 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2021 | 87 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2001 | 173 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2253 | 0.040 |
Why?
| | Chemokines, CXC | 1 | 2020 | 70 | 0.040 |
Why?
| | Fatal Outcome | 2 | 2005 | 303 | 0.040 |
Why?
| | Hospital Costs | 1 | 2021 | 117 | 0.040 |
Why?
| | Fatty Acid Desaturases | 1 | 2000 | 32 | 0.040 |
Why?
| | Pneumonia, Viral | 1 | 2005 | 373 | 0.040 |
Why?
| | Random Allocation | 1 | 2021 | 353 | 0.040 |
Why?
| | Placenta Growth Factor | 1 | 2019 | 24 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2001 | 389 | 0.040 |
Why?
| | Base Sequence | 1 | 2003 | 2181 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2001 | 352 | 0.040 |
Why?
| | Methotrexate | 1 | 2001 | 260 | 0.040 |
Why?
| | Neuropeptides | 1 | 2020 | 73 | 0.040 |
Why?
| | Bleomycin | 1 | 2001 | 248 | 0.040 |
Why?
| | Microtubule-Associated Proteins | 1 | 2001 | 196 | 0.040 |
Why?
| | Perioperative Period | 1 | 2019 | 56 | 0.040 |
Why?
| | Creatinine | 1 | 2001 | 499 | 0.040 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2000 | 188 | 0.040 |
Why?
| | Eye Proteins | 1 | 2020 | 92 | 0.040 |
Why?
| | Cost of Illness | 1 | 2021 | 308 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 2019 | 52 | 0.040 |
Why?
| | Doxorubicin | 1 | 2001 | 362 | 0.040 |
Why?
| | Microfilament Proteins | 1 | 2020 | 133 | 0.040 |
Why?
| | Cisplatin | 1 | 2001 | 320 | 0.040 |
Why?
| | Research Design | 1 | 2025 | 1139 | 0.040 |
Why?
| | Gene Silencing | 1 | 2020 | 195 | 0.040 |
Why?
| | Aging | 1 | 2009 | 1864 | 0.040 |
Why?
| | Homozygote | 1 | 2019 | 203 | 0.040 |
Why?
| | Loss of Heterozygosity | 1 | 2018 | 51 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 591 | 0.040 |
Why?
| | Patient Safety | 1 | 2021 | 314 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2020 | 480 | 0.030 |
Why?
| | Protein Phosphatase 2C | 1 | 2017 | 15 | 0.030 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 697 | 0.030 |
Why?
| | Janus Kinase 2 | 1 | 2017 | 32 | 0.030 |
Why?
| | Daunorubicin | 1 | 2016 | 26 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2018 | 413 | 0.030 |
Why?
| | Genes, p53 | 1 | 2017 | 72 | 0.030 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 455 | 0.030 |
Why?
| | Rhodamines | 1 | 2016 | 20 | 0.030 |
Why?
| | ZAP-70 Protein-Tyrosine Kinase | 1 | 2016 | 10 | 0.030 |
Why?
| | Radiography, Dual-Energy Scanned Projection | 1 | 2016 | 7 | 0.030 |
Why?
| | Ovarian Function Tests | 1 | 2016 | 1 | 0.030 |
Why?
| | Transplants | 1 | 2016 | 36 | 0.030 |
Why?
| | Premedication | 1 | 2016 | 44 | 0.030 |
Why?
| | Orthomyxoviridae | 1 | 2016 | 40 | 0.030 |
Why?
| | Validation Studies as Topic | 1 | 2016 | 22 | 0.030 |
Why?
| | Growth Substances | 1 | 2016 | 147 | 0.030 |
Why?
| | Calcineurin Inhibitors | 1 | 2016 | 72 | 0.030 |
Why?
| | CD4 Antigens | 1 | 2016 | 141 | 0.030 |
Why?
| | Myeloproliferative Disorders | 1 | 2016 | 27 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2016 | 141 | 0.030 |
Why?
| | Receptors, Virus | 1 | 2016 | 83 | 0.030 |
Why?
| | HT29 Cells | 1 | 2016 | 41 | 0.030 |
Why?
| | HLA-B Antigens | 1 | 2016 | 62 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2016 | 1946 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 554 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2003 | 1317 | 0.030 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2016 | 127 | 0.030 |
Why?
| | ras Proteins | 1 | 2017 | 153 | 0.030 |
Why?
| | Th1 Cells | 1 | 2016 | 143 | 0.030 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2016 | 113 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 399 | 0.030 |
Why?
| | Lung | 1 | 2009 | 4060 | 0.030 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2006 | 144 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2016 | 307 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 171 | 0.030 |
Why?
| | Biological Transport | 1 | 2016 | 418 | 0.030 |
Why?
| | Obesity | 1 | 2009 | 2992 | 0.030 |
Why?
| | Outpatients | 1 | 2019 | 396 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2015 | 2057 | 0.030 |
Why?
| | Angiopoietin-2 | 1 | 2015 | 16 | 0.030 |
Why?
| | Cadaver | 1 | 2016 | 296 | 0.030 |
Why?
| | Macrophages | 1 | 2023 | 1547 | 0.030 |
Why?
| | Protein Transport | 1 | 2016 | 445 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2020 | 712 | 0.030 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2015 | 40 | 0.030 |
Why?
| | History, 21st Century | 1 | 2016 | 213 | 0.030 |
Why?
| | Blotting, Western | 2 | 2011 | 1226 | 0.030 |
Why?
| | Immunotoxins | 1 | 2015 | 55 | 0.030 |
Why?
| | International Cooperation | 1 | 2015 | 198 | 0.030 |
Why?
| | Follicle Stimulating Hormone | 1 | 2016 | 244 | 0.030 |
Why?
| | Jaw | 1 | 2014 | 26 | 0.030 |
Why?
| | History, 20th Century | 1 | 2016 | 325 | 0.030 |
Why?
| | Diagnostic Errors | 1 | 1995 | 170 | 0.030 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2014 | 20 | 0.030 |
Why?
| | Hydroxamic Acids | 1 | 2014 | 89 | 0.030 |
Why?
| | Transduction, Genetic | 2 | 2005 | 127 | 0.030 |
Why?
| | Bones of Upper Extremity | 1 | 2013 | 3 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 978 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1570 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2016 | 3284 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2014 | 194 | 0.030 |
Why?
| | Spiro Compounds | 1 | 2013 | 14 | 0.030 |
Why?
| | Etoposide | 1 | 2013 | 158 | 0.030 |
Why?
| | ADAM17 Protein | 1 | 2013 | 35 | 0.030 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2013 | 94 | 0.030 |
Why?
| | Pericardiocentesis | 1 | 2013 | 9 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2014 | 218 | 0.030 |
Why?
| | Azacitidine | 1 | 2014 | 140 | 0.030 |
Why?
| | Autoimmunity | 1 | 2019 | 908 | 0.030 |
Why?
| | Lung Neoplasms | 2 | 2009 | 2526 | 0.030 |
Why?
| | Immunoglobulin Fragments | 1 | 2012 | 12 | 0.020 |
Why?
| | Myeloid Cells | 1 | 2014 | 148 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2015 | 385 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2014 | 382 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2015 | 512 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 976 | 0.020 |
Why?
| | Receptors, KIR2DL2 | 1 | 2011 | 6 | 0.020 |
Why?
| | Receptors, KIR2DL3 | 1 | 2011 | 9 | 0.020 |
Why?
| | Kinetics | 1 | 2015 | 1670 | 0.020 |
Why?
| | Remission, Spontaneous | 1 | 2011 | 40 | 0.020 |
Why?
| | Immunocompetence | 1 | 2011 | 42 | 0.020 |
Why?
| | Spine | 1 | 2013 | 173 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2016 | 660 | 0.020 |
Why?
| | Lysosomal-Associated Membrane Protein 1 | 1 | 2011 | 6 | 0.020 |
Why?
| | Terminology as Topic | 1 | 2013 | 216 | 0.020 |
Why?
| | Immune Tolerance | 1 | 2014 | 363 | 0.020 |
Why?
| | Piperidines | 1 | 2013 | 206 | 0.020 |
Why?
| | Stem Cells | 1 | 2016 | 594 | 0.020 |
Why?
| | Global Health | 1 | 2014 | 386 | 0.020 |
Why?
| | Femur | 1 | 2013 | 254 | 0.020 |
Why?
| | ABO Blood-Group System | 1 | 2011 | 51 | 0.020 |
Why?
| | Drug Synergism | 1 | 2011 | 382 | 0.020 |
Why?
| | Antilymphocyte Serum | 1 | 2010 | 66 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2011 | 346 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4565 | 0.020 |
Why?
| | Epitopes | 1 | 2012 | 479 | 0.020 |
Why?
| | Leukocyte Immunoglobulin-like Receptor B1 | 1 | 2010 | 2 | 0.020 |
Why?
| | Cell Division | 2 | 2002 | 794 | 0.020 |
Why?
| | Seasons | 1 | 2013 | 547 | 0.020 |
Why?
| | Algorithms | 1 | 2018 | 1704 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2016 | 1431 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2012 | 730 | 0.020 |
Why?
| | Virus Replication | 1 | 2011 | 483 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1242 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2012 | 1353 | 0.020 |
Why?
| | Cranial Irradiation | 1 | 2008 | 70 | 0.020 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2008 | 220 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2009 | 404 | 0.020 |
Why?
| | Quality of Life | 1 | 2019 | 2892 | 0.020 |
Why?
| | Umbilical Veins | 1 | 2007 | 62 | 0.020 |
Why?
| | Apolipoprotein C-I | 1 | 2006 | 1 | 0.020 |
Why?
| | Complement C1 Inactivator Proteins | 1 | 2006 | 6 | 0.020 |
Why?
| | Granzymes | 1 | 2007 | 50 | 0.020 |
Why?
| | Apolipoproteins C | 1 | 2006 | 4 | 0.020 |
Why?
| | Serum Amyloid A Protein | 1 | 2006 | 33 | 0.020 |
Why?
| | Prealbumin | 1 | 2006 | 30 | 0.020 |
Why?
| | Minnesota | 1 | 2007 | 164 | 0.020 |
Why?
| | Maternal Age | 1 | 2006 | 129 | 0.020 |
Why?
| | Blood Transfusion | 1 | 2008 | 325 | 0.020 |
Why?
| | DNA Primers | 1 | 2007 | 515 | 0.020 |
Why?
| | Peptide Mapping | 1 | 2005 | 64 | 0.020 |
Why?
| | Endotoxins | 1 | 2006 | 220 | 0.010 |
Why?
| | Reference Values | 1 | 2006 | 816 | 0.010 |
Why?
| | Kidney Neoplasms | 1 | 2009 | 403 | 0.010 |
Why?
| | Glycoproteins | 1 | 2006 | 342 | 0.010 |
Why?
| | Universities | 1 | 2007 | 433 | 0.010 |
Why?
| | Disease Progression | 1 | 2011 | 2757 | 0.010 |
Why?
| | Odds Ratio | 1 | 2006 | 1070 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2006 | 652 | 0.010 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2005 | 597 | 0.010 |
Why?
| | Cell Membrane | 1 | 2007 | 738 | 0.010 |
Why?
| | Lung Transplantation | 1 | 2006 | 313 | 0.010 |
Why?
| | Annexin A5 | 1 | 2003 | 25 | 0.010 |
Why?
| | Caspase 8 | 1 | 2003 | 48 | 0.010 |
Why?
| | Anion Exchange Protein 1, Erythrocyte | 1 | 2003 | 22 | 0.010 |
Why?
| | Erythropoiesis | 1 | 2003 | 55 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2005 | 430 | 0.010 |
Why?
| | Liver Neoplasms | 1 | 2009 | 786 | 0.010 |
Why?
| | Cytoskeletal Proteins | 1 | 2003 | 158 | 0.010 |
Why?
| | Membrane Potentials | 1 | 2003 | 284 | 0.010 |
Why?
| | Leukemia, B-Cell | 1 | 2002 | 13 | 0.010 |
Why?
| | Genes, Reporter | 1 | 2002 | 269 | 0.010 |
Why?
| | Caspases | 1 | 2003 | 247 | 0.010 |
Why?
| | Luciferases | 1 | 2002 | 150 | 0.010 |
Why?
| | Radiotherapy | 1 | 2002 | 201 | 0.010 |
Why?
| | Creatine | 1 | 2001 | 57 | 0.010 |
Why?
| | Hemolysis | 1 | 2003 | 206 | 0.010 |
Why?
| | Immunoblotting | 1 | 2001 | 308 | 0.010 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2001 | 49 | 0.010 |
Why?
| | Tissue Distribution | 1 | 2001 | 332 | 0.010 |
Why?
| | Models, Animal | 1 | 2002 | 384 | 0.010 |
Why?
| | Luminescent Proteins | 1 | 2002 | 179 | 0.010 |
Why?
| | Proteome | 1 | 2005 | 472 | 0.010 |
Why?
| | Blood Proteins | 1 | 2003 | 252 | 0.010 |
Why?
| | Forecasting | 1 | 2002 | 389 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 2001 | 257 | 0.010 |
Why?
| | Green Fluorescent Proteins | 1 | 2002 | 390 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2009 | 1040 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2001 | 560 | 0.010 |
Why?
| | RNA | 1 | 2007 | 921 | 0.010 |
Why?
| | Thymus Gland | 1 | 2001 | 312 | 0.010 |
Why?
| | Cell Death | 1 | 2001 | 374 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 2002 | 658 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2001 | 955 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2009 | 1291 | 0.010 |
Why?
| | Transfection | 1 | 2002 | 945 | 0.010 |
Why?
| | Spleen | 1 | 2001 | 514 | 0.010 |
Why?
| | Phosphorylation | 1 | 2001 | 1759 | 0.010 |
Why?
| | Gene Expression | 1 | 2001 | 1502 | 0.010 |
Why?
|
|
Verneris's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|